Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE4B | Q07343 | 18/20 | 0.49 |
| ▸ | PDE4D | Q08499 | 3/20 | 0.49 |
| ▸ | TRPV1 | Q8NER1 | 1/20 | 0.48 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9986954 | 0.83 | TRPV1 (0.50) | PDE4BPDE4DTRPV1KMT2A | |
| SCHEMBL9987237 | 0.79 | ALDH1A1 (0.55) | — | |
| SCHEMBL10674017 | 0.78 | KMT2A (0.49) | PDE4BPDE4DTRPV1KMT2A | |
| Hydrochloric Acid SCHEMBL27732942 | 0.78 | TRPV1 (0.46) | PDE4BPDE4DTRPV1KMT2A | |
| SCHEMBL9987982 | 0.76 | PDE4B (0.46) | PDE4BPDE4D | |
| SCHEMBL27732903 | 0.75 | TRPV1 (0.43) | PDE4BPDE4DTRPV1KMT2A | |
| SCHEMBL9986022 | 0.74 | KMT2A (0.42) | PDE4BPDE4DTRPV1KMT2A | |
| SCHEMBL31092822 | 0.74 | PDE4B (0.48) | PDE4BPDE4DTRPV1 | |
| SCHEMBL9987983 | 0.74 | PDE4B (0.48) | PDE4BPDE4DTRPV1 | |
| SCHEMBL9986633 | 0.73 | PDE4B (0.41) | PDE4BPDE4DTRPV1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9062055-B2 | Fused pyrrole derivatives as PI3K inhibitors | INCYTE CORPORATION (US) | 2015-06-23 | — | — | US | disclosed |
| US-9062055-B2 | Fused pyrrole derivatives as PI3K inhibitors | INCYTE CORPORATION (US) | 2015-06-23 | — | — | US | disclosed |
| US-9062055-B2 | Fused pyrrole derivatives as PI3K inhibitors | INCYTE CORPORATION (US) | 2015-06-23 | — | — | US | disclosed |
| WO-2011163195-A1 | FUSED PYRROLE DERIVATIVES AS PI3K INHIBITORS | INCYTE CORPORATION (US) | 2011-12-29 | — | — | WO | disclosed |
| WO-2011163195-A1 | FUSED PYRROLE DERIVATIVES AS PI3K INHIBITORS | INCYTE CORPORATION (US) | 2011-12-29 | — | — | WO | disclosed |
| US-20110312979-A1 | FUSED PYRROLE DERIVATIVES AS PI3K INHIBITORS | INCYTE CORPORATION | 2011-12-22 | — | — | US | disclosed |
| US-20110312979-A1 | FUSED PYRROLE DERIVATIVES AS PI3K INHIBITORS | INCYTE CORPORATION | 2011-12-22 | — | — | US | disclosed |
| US-20110312979-A1 | FUSED PYRROLE DERIVATIVES AS PI3K INHIBITORS | INCYTE CORPORATION | 2011-12-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110312979-A1 | FUSED PYRROLE DERIVATIVES AS PI3K INHIBITORS | PIK3R5, PIK3R4, PIK3CA | PDE4B 2790/4885PDE4D 2869/4885TRPV1 3411/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.